BioCentury | Apr 8, 2019
Company News

Management tracks: WuXi AppTec, Kymab, Acceleron

WuXi AppTec Co. Ltd. (Shanghai:603259; HKSE:2359) hired Frederick Hausheer as CMO. He was CEO of Alpha Omega Oncology Services (San Antonio, Texas) and an associate partner at Alacrita Consulting (Waltham, Mass.). Antibody company Kymab Group...
BioCentury | Apr 2, 2019
Company News

Lonza, Chr. Hansen forming CDMO for live biotherapeutics

Lonza and Chr. Hansen formed a joint venture to establish a contract development and manufacturing organization for end-to-end manufacturing of live biotherapeutics, including microbiome products. Chr. Hansen A/S (Hoersholm, Denmark) and Lonza Group Ltd. (SIX:LONN)...
BioCentury | Dec 7, 2018
Financial News

Salubris leads Viracta venture round, gets Chinese rights to cancer therapy

Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294) led a series C round for Viracta Therapeutics Inc. (San Diego, Calif.) on Dec. 4 and gained Chinese rights to develop Viracta’s nanatinostat (VRx-3996) in combination with an antiviral...
BioCentury | Dec 4, 2018
Financial News

Salubris leads Viracta venture round, gets Chinese rights to cancer therapy

Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294) led a series C round for Viracta Therapeutics Inc. (San Diego, Calif.) on Tuesday and gained Chinese rights to develop Viracta’s nanatinostat (VRx-3996) in combination with an antiviral to...
BioCentury | Aug 16, 2018
Distillery Therapeutics

Neurology

...a tool compound 5-HT1B receptor agonist or dorsal raphe-specific expression of the light-responsive neuron-activating channelrhodopsin-2 (ChR2...
...Aug. 8, 2018 doi:10.1038/s41586-018-0416-4 CONTACT: Robert Malenka, Stanford University, Stanford, Calif. email: malenka@stanford.edu Hongjiang Li Stanford University Channelrhodopsin-2 (ChR2) Serotonin...
BioCentury | Jun 7, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: May 2018

New Therapeutic Targets and Biomarkers: May 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during May 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | May 9, 2018
Distillery Therapeutics

Otologic

INDICATION: Hearing loss Mouse studies suggest optogenetic therapy using an engineered mutant of the C. noctigama channelrhodopsin Chrimson could help treat age-related hearing loss. The mutant is a version of Chrimson engineered to inactivate quickly...
BioCentury | May 3, 2018
Preclinical News

Optogenetic cochlea implants to treat hearing loss

In a Nature Communications paper , scientists at Max Planck Institute of Biophysics and colleagues suggested that optogenetic cochlear implants that use a light-stimulated ion channel engineered with increased neural photoactivation could help treat hearing loss....
BioCentury | Apr 13, 2018
Clinical News

Viracta starts Phase Ib/II of VRx-3996 for Epstein-Barr virus-positive lymphomas

Viracta Therapeutics Inc. (San Diego, Calif.) began the Phase Ib/II VT3996-201 trial of VRx-3996 (chr-3996) in combination with valganciclovir to treat Epstein-Barr virus-positive lymphomas. The open-label, U.S. trial is enrolling up to 40 patients. The...
BioCentury | Sep 12, 2016
Company News

RetroSense Therapeutics, Allergan deal

...retinitis pigmentosa (RP) candidate RST-001 , an adeno-associated virus (AAV) 2 vector activating the channelrhodopsin-2 (ChR2...
Items per page:
1 - 10 of 119